NCT06726148 2026-04-17
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT06998407 2026-04-03
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07389733 2026-04-03
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05735080 2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT06110793 2026-03-30
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07109726 2026-03-23
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting